KaloBios CEO to Participate in Pharmaceutical Strategy Conference
BRISBANE, Calif., Sept. 27, 2016 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that Cameron Durrant, MD, chairman and CEO, will speak at the Pharmaceutical Strategy Conference in New York City September 28-30, 2016. Dr. Durrant will discuss how innovative paradigms, such as the company’s Responsible Pricing Model, can make a transformative impact on two critical issues facing the industry: reputation and pricing.
“The Responsible Pricing Model is a leading commitment to operate in a new way, embedding affordability, transparency and reasonable return into our pricing as we execute our strategy to bring needed medicines to patients,” said Dr. Durrant. “We are pleased to be part of the Pharmaceutical Strategy Conference to connect with like-minded stakeholders and lead real progress for our industry.”
Details of the discussion panels follow:
Title: Industry Image Panel: Confronting Pharma’s Reputation Problem
Date: Thursday, September 29, 2016, 2:00 p.m. EDT
Participants: Dr. Cameron Durrant, KaloBios Pharmaceuticals; Dr. Benjamin Cowen, Milestone Pharmaceuticals; Lucy Abreu, Otsuka Pharmaceutical Companies; Gautam Gupta, Pfizer
Title: Reimbursement / Market Access Focus Panel: The Road To Value-Based Drug Pricing
Date: Friday, September 30, 2016, 9:15 a.m. EDT
Participants: Dr. Edmund Pezalla, Aetna; David Gilman, Huron Consulting; Dr. Cameron Durrant, KaloBios Pharmaceuticals; Nathan Dowden, Rubius Therapeutics; Richard Ascroft, Takeda Pharmaceuticals
For more information on the conference, please visit https://lifesciences.knect365.com/pharmaceutical-strategy/.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers such as CMML and potentially JMML. For more information, visit www.kalobios.com.
This release contains forward-looking statements that are intended to be subject to protection afforded by the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as “will,” “expect,” “intend,” “plan,” “potential,” “possible,” “goals,” “accelerate,” “continue,” and similar expressions identify forward-looking statements, including, without limitation, statements related to expectations regarding the Company’s product candidates; the Company’s opportunity to benefit from the application of our Responsible Pricing Model; and expectations for the Company’s future financial position. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the uncertainties inherent in the development and launch of any new pharmaceutical product; our ability to successfully and timely complete clinical trials for our drug candidates in clinical development; our ability to obtain the necessary U.S. and international regulatory approvals for our drug candidates and to qualify for or benefit from various regulatory incentives; the scope and validity of intellectual property and other competitive protection for our drug candidates; our ability to identify, in-license and acquire additional product candidates or to form partnerships for the sale, licensing, collaborative development or marketing of our existing product candidates; our ability to maintain or engage third-party manufacturers to manufacture, supply, store and distribute supplies of our drug candidates for our clinical trials; our lack of profitability and the need for additional capital to operate our business; and the success of any product; and the various risks and uncertainties described in the "Risk Factors" and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.
CONTACT: Investors: Kim Sutton Golodetz O: 212-838-3777 KGolodetz@lhai.com Bruce Voss O: 310-691-7100 BVoss@lhai.com Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 email@example.com
Released September 27, 2016